Related Experiment Video

Updated: Mar 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Immune Checkpoint Therapies in Prostate Cancer

Sangeeta Goswami1, Ana Aparicio, Sumit K Subudhi

  • 1From the Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Cancer Journal (Sudbury, Mass.)
|April 26, 2016
PubMed

Insights

Advanced prostate cancer, a leading cause of cancer death, shows promise with immunotherapy. Immune checkpoint therapies offer limited benefit, highlighting the need for better patient selection and understanding of the tumor microenvironment.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Advanced prostate cancer is a significant cause of cancer mortality in the US.
  • Prostate cancer was the first malignancy to show improved survival with a cancer vaccine, proving immune responsiveness.
  • Immune checkpoint therapies have shown limited success in metastatic prostate cancer.

Purpose of the Study:

  • To review current data on immune checkpoint therapies in prostate cancer.
  • To propose future directions for improving treatment efficacy.

Main Methods:

  • Review of existing clinical data and research on immune checkpoint inhibitors in prostate cancer.
  • Analysis of factors influencing treatment response, including patient selection and tumor microenvironment characteristics.

Main Results:

  • Limited clinical benefit observed with current immune checkpoint therapies in a subset of patients.
  • Patient selection and tumor microenvironment are critical factors influencing response.
  • Prostate cancer is an immune-responsive disease, but current therapies face challenges.

Conclusions:

  • Further research is needed to optimize patient selection for immune checkpoint therapies.
  • Understanding and targeting the tumor microenvironment is crucial for enhancing treatment outcomes.
  • Future strategies should focus on overcoming resistance mechanisms to improve survival in advanced prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K